Role of the MRP1/ABCC1 multidrug transporter protein in cancer - PubMed (original) (raw)

Review

Role of the MRP1/ABCC1 multidrug transporter protein in cancer

Marcia Munoz et al. IUBMB Life. 2007 Dec.

Free article

Abstract

Multidrug resistance is a major obstacle to cancer treatment and leads to poor prognosis for the patient. Multidrug resistance-associated protein 1 (MRP1) transports a wide range of therapeutic agents as well as diverse physiological substrates and may play a role in the development of drug resistance in several cancers including those of the lung, breast and prostate, as well as childhood neuroblastoma. The majority of patients with neuroblastoma present with widely disseminated disease at diagnosis and despite intensive treatment, the prognosis for such patients is dismal. There is increasing evidence that MRP1 is a MYCN target gene involved in the development of multidrug resistance in neuroblastoma. Given the importance of MRP1 overexpression in neuroblastoma, MRP1 inhibition may be a clinically relevant approach to improving patient outcome in this disease.

PubMed Disclaimer

Similar articles

• Association of high-level MRP1 expression with poor clinical outcome in a large prospective study of primary neuroblastoma.
  Haber M, Smith J, Bordow SB, Flemming C, Cohn SL, London WB, Marshall GM, Norris MD. Haber M, et al. J Clin Oncol. 2006 Apr 1;24(10):1546-53. doi: 10.1200/JCO.2005.01.6196. J Clin Oncol. 2006. PMID: 16575006
• The role of the multidrug resistance-associated protein 1 gene in neuroblastoma biology and clinical outcome.
  Pajic M, Norris MD, Cohn SL, Haber M. Pajic M, et al. Cancer Lett. 2005 Oct 18;228(1-2):241-6. doi: 10.1016/j.canlet.2005.01.060. Cancer Lett. 2005. PMID: 15979785 Review.
• ABC transporters and neuroblastoma.
  Yu DM, Huynh T, Truong AM, Haber M, Norris MD. Yu DM, et al. Adv Cancer Res. 2015;125:139-70. doi: 10.1016/bs.acr.2014.10.005. Epub 2015 Jan 8. Adv Cancer Res. 2015. PMID: 25640269
• ABCC multidrug transporters in childhood neuroblastoma: clinical and biological effects independent of cytotoxic drug efflux.
  Henderson MJ, Haber M, Porro A, Munoz MA, Iraci N, Xue C, Murray J, Flemming CL, Smith J, Fletcher JI, Gherardi S, Kwek CK, Russell AJ, Valli E, London WB, Buxton AB, Ashton LJ, Sartorelli AC, Cohn SL, Schwab M, Marshall GM, Perini G, Norris MD. Henderson MJ, et al. J Natl Cancer Inst. 2011 Aug 17;103(16):1236-51. doi: 10.1093/jnci/djr256. Epub 2011 Jul 28. J Natl Cancer Inst. 2011. PMID: 21799180 Free PMC article.
• Importance of ABCC1 for cancer therapy and prognosis.
  Kunická T, Souček P. Kunická T, et al. Drug Metab Rev. 2014 Aug;46(3):325-42. doi: 10.3109/03602532.2014.901348. Epub 2014 Mar 26. Drug Metab Rev. 2014. PMID: 24670052 Review.

Cited by

• TFEB controls sensitivity to chemotherapy and immuno-killing in non-small cell lung cancer.
  Akman M, Monteleone C, Doronzo G, Godel M, Napoli F, Merlini A, Campani V, Nele V, Balmas E, Chontorotzea T, Fontana S, Digiovanni S, Barbu FA, Astanina E, Jafari N, Salaroglio IC, Kopecka J, De Rosa G, Mohr T, Bertero A, Righi L, Novello S, Scagliotti GV, Bussolino F, Riganti C. Akman M, et al. J Exp Clin Cancer Res. 2024 Aug 7;43(1):219. doi: 10.1186/s13046-024-03142-4. J Exp Clin Cancer Res. 2024. PMID: 39107857 Free PMC article.
• Cytotoxicity and reversal effect of sertraline, fluoxetine, and citalopram on MRP1- and MRP7-mediated MDR.
  Bin Kanner Y, Teng QX, Ganoth A, Peer D, Wang JQ, Chen ZS, Tsfadia Y. Bin Kanner Y, et al. Front Pharmacol. 2023 Nov 2;14:1290255. doi: 10.3389/fphar.2023.1290255. eCollection 2023. Front Pharmacol. 2023. PMID: 38026953 Free PMC article.
• Landscape of NcRNAs involved in drug resistance of breast cancer.
  Kang Y. Kang Y. Clin Transl Oncol. 2023 Jul;25(7):1869-1892. doi: 10.1007/s12094-023-03189-3. Epub 2023 Apr 17. Clin Transl Oncol. 2023. PMID: 37067729 Free PMC article. Review.
• Effective Drug Delivery in Diffuse Intrinsic Pontine Glioma: A Theoretical Model to Identify Potential Candidates.
  El-Khouly FE, van Vuurden DG, Stroink T, Hulleman E, Kaspers GJL, Hendrikse NH, Veldhuijzen van Zanten SEM. El-Khouly FE, et al. Front Oncol. 2017 Oct 30;7:254. doi: 10.3389/fonc.2017.00254. eCollection 2017. Front Oncol. 2017. PMID: 29164054 Free PMC article.
• "Keaping" a lid on lung cancer: the Keap1-Nrf2 pathway.
  Best SA, Sutherland KD. Best SA, et al. Cell Cycle. 2018;17(14):1696-1707. doi: 10.1080/15384101.2018.1496756. Epub 2018 Aug 1. Cell Cycle. 2018. PMID: 30009666 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Wiley

• Other Literature Sources

  • The Lens - Patent Citations Database

• Research Materials

  • NCI CPTC Antibody Characterization Program